Quarterly ResultApr 29, 2026, 07:07 AM
BLCO Q1 Revenue +9% to $1.244B; Net Loss $71M; Raises FY26 Guidance
AI Summary
Bausch + Lomb Corporation announced strong first-quarter 2026 financial results, with revenue increasing 9% to $1.244 billion. The company significantly reduced its GAAP net loss to $71 million from $212 million in the prior year, driven by revenue growth and operating efficiencies. Based on this performance and a positive outlook, Bausch + Lomb raised its full-year 2026 revenue and Adjusted EBITDA guidance. Growth was notably strong in Pharmaceuticals, led by MIEBO and XIIDRA, and across its dry eye portfolio and premium intraocular lenses.
Key Highlights
- Raised full-year 2026 revenue guidance to $5.420B-$5.520B.
- Raised full-year 2026 Adjusted EBITDA guidance to $1.010B-$1.060B.
- Q1 2026 revenue was $1.244 billion, up 9% (6% constant currency) YoY.
- Q1 2026 GAAP Net Loss was $71 million, an improvement from $212 million loss YoY.
- Q1 2026 Adjusted EBITDA was $189 million, up $91 million YoY.
- Pharmaceuticals segment revenue grew 14% (12% constant currency) to $305 million.
- Vision Care segment revenue grew 8% (5% constant currency) to $711 million.
- Surgical segment revenue grew 7% (1% constant currency) to $228 million.